We are live on ! Find out more
VA

VR Adviser Portfolio holdings

AUM $2.68B
1-Year Est. Return 422.73%
This Fund
S&P 500
This Quarter Est. Return
+46.01%
1 Year Est. Return
+422.73%
3 Year Est. Return
+1,447.09%
5 Year Est. Return
+3,249.52%
10 Year Est. Return
–
AUM
$648M
AUM Growth
+$140M
Cap. Flow
+$12.9M
Cap. Flow %
1.99%
Top 10 Hldgs %
69.93%
Holding
36
New
9
Increased
7
Reduced
3
Closed
5

Top Buys

Rank Stock Value
1
GOSS icon
Gossamer Bio
GOSS
+$21.7M
2
TCDA
Tricida, Inc. Common Stock
TCDA
+$21M
3
PLRX icon
Pliant Therapeutics
PLRX
+$20.7M
4
MIST icon
Milestone Pharmaceuticals
MIST
+$18.4M
5
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$13.9M

Top Sells

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$41.5M
2
CLDX icon
Celldex Therapeutics
CLDX
+$24.2M
3
RLMD icon
Relmada Therapeutics
RLMD
+$20.8M
4
VTGN icon
VistaGen Therapeutics
VTGN
+$18.2M
5
WHWK
Whitehawk Therapeutics
WHWK
+$14.5M

Sector Composition

Rank Sector Weight
1 Healthcare 96.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TCDA
1
DELISTED
Tricida, Inc. Common Stock
TCDA
$94.8M 14.63%
9,050,064
+1,917,985
+27% +$21M
ACRS icon
2
Aclaris Therapeutics
ACRS
$726M
$71.8M 11.08%
4,563,962
– –
COGT icon
3
Cogent Biosciences
COGT
$6.65B
$60.2M 9.3%
4,038,117
– –
RLMD icon
4
Relmada Therapeutics
RLMD
$557M
$56.2M 8.67%
1,518,056
-752,016
-33% -$20.8M
VRDN icon
5
Viridian Therapeutics
VRDN
$2.09B
$43.7M 6.74%
2,130,308
+277,389
+15% +$4.99M
GHRS icon
6
GH Research
GHRS
$1.93B
$38.7M 5.98%
3,333,154
+147,581
+5% +$1.86M
PLRX icon
7
Pliant Therapeutics
PLRX
$64.4M
$22.6M 3.48%
+1,080,000
New +$20.7M
MIST icon
8
Milestone Pharmaceuticals
MIST
$138M
$22.3M 3.44%
+2,425,737
New +$18.4M
TERN
9
DELISTED
Terns Pharmaceuticals
TERN
$21.8M 3.37%
+3,707,891
New +$13.8M
MRNS
10
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$21M 3.24%
3,156,803
– –
GOSS icon
11
Gossamer Bio
GOSS
$82.9M
$20.9M 3.23%
+1,747,000
New +$21.7M
ANNX icon
12
Annexon
ANNX
$834M
$19.9M 3.07%
3,220,050
+1,291,573
+67% +$6.98M
TIL icon
13
Instil Bio
TIL
$48.3M
$19.9M 3.07%
205,289
-94,594
-32% -$10.8M
AKUS
14
DELISTED
Akouos Inc
AKUS
$18.9M 2.92%
2,800,566
+133,447
+5% +$500K
DICE
15
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$15.5M 2.39%
+764,979
New +$13.9M
JBIO
16
Jade Biosciences
JBIO
$1.2B
$13.8M 2.13%
23,826
+6,957
+41% +$4.64M
LIAN
17
DELISTED
LianBio American Depositary Shares
LIAN
$10.8M 1.66%
5,378,341
– –
FULC icon
18
Fulcrum Therapeutics
FULC
$273M
$9.71M 1.5%
+1,200,000
New +$8.59M
INZY
19
DELISTED
Inozyme Pharma
INZY
$7.26M 1.12%
2,709,987
– –
VTYX
20
DELISTED
Ventyx Biosciences
VTYX
$7.26M 1.12%
+207,925
New +$4.6M
RXDX
21
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$7.18M 1.11%
+121,663
New +$5.57M
SVRA icon
22
Savara
SVRA
$1.12B
$7.06M 1.09%
4,555,038
+437,508
+11% +$704K
PRVB
23
DELISTED
Provention Bio, Inc. Common Stock
PRVB
$5.03M 0.78%
1,118,653
– –
ALT icon
24
Altimmune
ALT
$552M
$4.72M 0.73%
369,306
– –
TRVI icon
25
Trevi Therapeutics
TRVI
$2.59B
$4.7M 0.72%
3,050,022
– –
1
2

Similar funds

MMEA
Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return
WGI
Westwood Global Investments Boston, Massachusetts $2.68B AUM 76.4% 1-Year Est. Return
TCAM
Turtle Creek Asset Management Toronto, Ontario, Canada $2.67B AUM 0.64% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
HC
Henshaw Capital Woburn, Massachusetts $2.7B AUM 29.67% 1-Year Est. Return
CI
Capital International Los Angeles, California $2.7B AUM 31.08% 1-Year Est. Return
PCA
Pallas Capital Advisors Braintree, Massachusetts $2.66B AUM 22.31% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return

VR Adviser's Q3 2022 Portfolio in Review

As of Q3 2022, VR Adviser held 36 positions worth $648M, up 28% from $508M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

VR Adviser's Q3 2022 filing shows 9 new, 7 increased, 3 reduced and 5 closed positions. Its largest new stake was Gossamer Bio: 1,747,000 shares worth $20.9M. The largest sale was Travere Therapeutics, an estimated $41.5M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier.

  • VR Adviser's largest Q3 2022 buy was Gossamer Bio: 1,747,000 shares worth $20.9M.
  • VR Adviser added most to Tricida, Inc. Common Stock in Q3 2022, an estimated $21M increase.
  • VR Adviser's biggest Q3 2022 reduction was Celldex Therapeutics, cutting an estimated $24.2M.
  • VR Adviser fully exited Travere Therapeutics in Q3 2022, selling an estimated $41.5M.
  • VR Adviser's ten largest holdings make up 70% of its $648M portfolio in Q3 2022.
  • VR Adviser opened 9 new positions and closed 5 in Q3 2022.
  • VR Adviser's portfolio value rose 28% quarter-over-quarter to $648M.

Based on VR Adviser's 13F filing for Q3 2022, filed 14 Nov 2022.